Peregrine Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Peregrine Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-514,362	Closed	-$12.3M	–	333
2019 Q4	$12.3M	Buy	514,362 +37,499	+8%	+$1.03M	0.31%	129
2019 Q3	$12.8M	Buy	476,863 +12,398	+3%	+$348K	0.35%	125
2019 Q2	$12.6M	Buy	464,465 +37,157	+9%	+$1.17M	0.31%	135
2019 Q1	$14.8M	Sell	427,308 -117,055	-22%	-$3.38M	0.37%	124
2018 Q4	$10.6M	Buy	+544,363	New	+$11.2M	0.3%	141
2017 Q1	–	Sell	-459,367	Closed	-$10.3M	–	266
2016 Q4	$10.3M	Buy	459,367 +7,799	+2%	+$152K	0.27%	165
2016 Q3	$10.3M	Buy	+451,568	New	+$10.6M	0.27%	161

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Peregrine Capital Management's PTLA Position: Q1 2020 in Review

Peregrine Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 514,362 shares — an estimated $12.3M sold.

Peregrine Capital Management first reported a position in PTLA in Q3 2016 and held it in 7 quarters. The position peaked at $14.8M in Q1 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Peregrine Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Peregrine Capital Management sold 514,362 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $12.3M.
Peregrine Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2016 and held it in 7 quarters.
Peregrine Capital Management's Portola Pharmaceuticals, Inc. position peaked at $14.8M in Q1 2019.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Peregrine Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.